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Abstract
Background: Not all cancer patients receive state-of-the-art care and providing regular feedback
to clinicians might reduce this problem. The purpose of this study was to assess the utility of various
data sources in providing feedback on the quality of cancer care.
Methods: Published clinical practice guidelines were used to obtain a list of processes-of-care of
interest to clinicians. These were assigned to one of four data categories according to their
availability and the marginal cost of using them for feedback.
Results: Only 8 (3%) of 243 processes-of-care could be measured using population-based registry
or administrative inpatient data (lowest cost). A further 119 (49%) could be measured using a core
clinical registry, which contains information on important prognostic factors (e.g., clinical stage,
physiological reserve, hormone-receptor status). Another 88 (36%) required an expanded clinical
registry or medical record review; mainly because they concerned long-term management of
disease progression (recurrences and metastases) and 28 (11.5%) required patient interview or
audio-taping of consultations because they involved information sharing between clinician and
patient.
Conclusion: The advantages of population-based cancer registries and administrative inpatient
data are wide coverage and low cost. The disadvantage is that they currently contain information
on only a few processes-of-care. In most jurisdictions, clinical cancer registries, which can be used
to report on many more processes-of-care, do not cover smaller hospitals. If we are to provide
feedback about all patients, not just those in larger academic hospitals with the most developed
data systems, then we need to develop sustainable population-based data systems that capture
information on prognostic factors at the time of initial diagnosis and information on management
of disease progression.
Background
There is a perception, supported by some evidence, that not
all cancer patients receive state-of-the-art care.[1-3] Provid-
ing regular feedback to clinicians might reduce this prob-
lem[1] and supporting this contention is a Cochrane review,
which found that regular feedback can provide moderate,
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studies from the United States also suggest that timely report-
ing and feedback improves quality-of-care.[5,6]
Feedback about quality of care needs to be done at a sustain-
able cost, which is not an easy task. For example, in 1990,
California's assembly debated new requirements for report-
ing clinical indicators to assess quality of care. When the cost
of collecting the data items for the clinical indicators was esti-
mated at $61 M, fiscal reality intervened and the legislature
mandated the use of quality measures that used California's
existing routinely-maintained databases.[7]
The aim of this current study was to determine what data
are needed to provide feedback on measures of interest to
clinicians, who treat cancer patients. Feedback cannot be
done without data; hence it is important to understand
the utility of current data sources. We grouped data
sources into four categories based on their availability and
the marginal cost of using them for feedback. Published
clinical practice guidelines were used to identify proc-
esses-of-care of interest to clinicians.
We were particularly interested in the utility of popula-
tion-based cancer registries and administrative inpatient
data, which are attractive sources of data for feedback
because they have wide coverage. Also, because they are
maintained primarily for other purposes, they can provide
feedback at small marginal cost.
Several studies have assessed the quality of data in various
databases designed to measure quality of cancer care.[8-
10] To our knowledge, this is the first study to describe the
utility of various data sources in providing feedback on
cancer care.
Methods
Categories of data
Possible sources of data for regular feedback include
administrative inpatient databases, population-based
cancer registries, (hospital-based) clinical cancer regis-
tries, medical record review, patient interview and audio-
taping of consultations. We grouped these data sources
into four categories based on the marginal cost of using
them for feedback from least (Category 1) to most expen-
sive. (Table 1)
The primary purpose of administrative inpatient data is
related to billing patients and funding hospitals[7], while
for population-based cancer registries (at least in most
jurisdictions to date) the primary purpose is to measure
incidence, prevalence, mortality and population-based
relative survival.[11] Therefore they are secondary data
sources for the purpose of measuring quality of cancer
care, and can therefore provide this information at low
marginal cost. In contrast, the primary purpose of the
other data sources, listed in Table 1, is to measure the
quality of cancer care and consequently, there are no cost
offsets. We ranked a "core clinical registry" as less costly
than an "extended clinical registry" because the data items
that define an "extended clinical registry" are more diffi-
cult and time-consuming to collect and therefore more
costly.
As with any categorisation scheme, it is a useful frame-
work, but we make no claim that it is perfect. For example,
the distinction between population-based and (hospital-
based) clinical cancer registries is less clear-cut than it used
to be[12] with some population-based registries augment-
ing their data with information on clinical stage.[8] How-
ever, because this is not widespread in most jurisdictions
(at least at present) we assigned feedback measures reliant
on clinical stage to Category 2: core clinical registry;
whereas those based on broader staging information (e.g.,
regional or distant spread) such as recorded by SEER[13]
were assigned to Category 1.
Clinical registries are also constantly evolving and can
vary. To identify data items that could reasonably be
assumed to comprise a typical clinical registry, we used
the Minimum Data Set for Clinical Cancer Registration
from New South Wales, Australia.[14] It is based on clin-
ical registries in the United States, United Kingdom and
Canada and it represents a fairly typical minimum clinical
data set. Under our schema, The National Cancer Data
Base (American College of Surgeons) would be classified
as a core clinical registry. It collects information on patient
characteristics, tumour staging and histology, type of first
course treatment administered, disease recurrence and
survival.[15]
Clinical registries have emphasised initial diagnostic pro-
cedures and initial therapies because they were thought to
have the greatest influence on survival.[16] We therefore
allocated processes-of-care related to longer term follow-
up or management of recurrences or metastases to Cate-
gory 3: extended clinical registry or medical record review
(Table 1). Also included in Category 3were guidelines
based on surgical techniques, because unlike the date and
type of inpatient surgery, they are not captured in routine-
inpatient data (i.e., Category 1).
Finally, we assigned to Category 4 all those guidelines that
dealt with information sharing between clinicians and
patients. These were mainly guidelines recommending
that the clinician communicate certain information to the
patient so that he or she could make an informed deci-
sion. For example, one of the melanoma guidelines is that
patients should be provided with adequate information
about prognosis because this is associated with enhanced
patient well-being. While such information could be rou-
tinely collected if clinicians documented their discussionsPage 2 of 6
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the exception, rather than standard practice and so typi-
cally requires costly, one-off studies. [17]
Processes-of-care
To obtain a list of processes-of-care of interest to clini-
cians, we used published Australian guidelines for the
four of the five most common cancers diagnosed in Aus-
tralia; that is, colorectal[18], breast (published separately
for early and advanced)[19,20], and lung cancer[21], and
melanoma.[22] The Australian guidelines for prostate
cancer (the commonest cancer among Australian men)
are rudimentary in that they comprise only four guide-
lines, each of which relates to providing information to
patients about treatment options for localised dis-
ease.[23] We therefore decided not to include prostate
cancer guidelines in this study.
Where the Australian guidelines were evidence-based,
they relied primarily on international studies, so their
content should reflect processes-of-care of interest to clini-
cians in most jurisdictions. Where it was not possible for
them to be evidence-based (i.e., evidence was lacking)
they represent the consensus view of opinion leaders in
the field and again should encompass aspects of cancer
management of interest to clinicians in most jurisdictions.
Although the quality of guidelines can vary across jurisdic-
tions, there is much less scope for the content of the guide-
lines to vary. [24]
We were interested in the direct clinical management of can-
cer patients and therefore excluded guidelines that summa-
rised information on risk factors, epidemiology, and the
mechanics of various pathology procedures or investigation
of patients with suspicious symptoms not yet proven to be
Table 1: Categories of data to measure adherence to guidelines
Data items
Category 1
Population-based cancer registry, with or with linkage to 
administrative inpatient data
Demographics
Site of cancer
Morphology
Summary staging information at time of diagnosis 
(local, regional, distant spread)
Type and date of inpatient surgery
Co-morbidities (pre-existing and complications)
Category 2
Core clinical registry Type and date of initial treatments
Intent of treatment (curative versus palliative)
Clinical (TNM) stage at diagnosis
Performance status
Specific prognostic factors 
(e.g., hormone receptor status for breast cancer)
Assessment by multidisciplinary team
Participation in clinical trial
Category 3
Extended clinical registry or medical record review Long-term follow up
Management of disease progression
Management of complications of cancer therapies 
(e.g., anti-emetics, heparin)
Details of surgical techniques 
(e.g., omental covering of anastomosis, on-table colonic lavage)
Category 4
Patient interview Information sharing between clinicians and patients, for example
Audio-taping of consultation • Method of breaking bad news
• Inquiries about how spouse and children were coping
• Resolution of family conflicts
• Information provided to help woman choose between breast-
conserving surgery and mastectomyPage 3 of 6
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excluded 72 (23%), leaving 243 guidelines to assess.
Assessment
All four of us independently assigned each process-of-care
(based on a guideline) to one of the four data categories.
Given the clear-cut categorisation of data sources and data
items (Table 1), disagreements were uncommon (<2% of
feedback measures) and were discussed until consensus
was reached. A process-of-care that could be assigned to
more than one data category was assigned to the least
costly category.
Results
Type of data required for measurement
Only 8 of 243 processes-of-care (3.3%) could be reported
using a population-based registry or administrative inpa-
tient data, either linked or unlinked (Category 1); Table 2.
Although nearly half of the guidelines (119 or 49.0%)
could be measured using a core clinical registry (Category
2), 88 (36.1%) required an expanded clinical registry or
medical record review (Category 3) because they were
based on information about follow-up or management of
disease progression. A further 28 (11.5%) of the guide-
lines were classified to Category 4(patient interview or
audio-taping of consultation).
The main reasons why population-based cancer registries
and administrative inpatient data can be used to measure
so few processes-of-care are shown in column 2 (Type of
guideline) of Table 2. Numerically, two reasons stand out
from the others. The first is the lack of information on
prognostic factors such as clinical stage at diagnosis, phys-
iological reserve (i.e., measures of performance status
such as Karnofsky score or ECOG status) and hormone-
receptor status. Specifically, 39.5% of the processes-of-
Table 2: Data category by feedback measure and type of cancer
Data category Type of guideline n (%)
Early breast Advanced breast Colorectal Lung Melanoma Total
Category 1 Level of hospital 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.2%) 0 (0.0%) 1 (0.4%)
Population-based 
registry, routine-
inpatient data
Surgery; guideline not reliant on 
clinical stage
0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (4.8%) 3 (7.3%) 7 (2.9%)
Sub-total 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (6.0%) 3 (7.3%) 8 (3.3%)
Category 2 Initial diagnostic or staging 
procedures
0 (0.0%) 0 (0.0%) 2 (4.3%) 14 (16.9% 3 (7.3%) 19 (7.8%)
Core clinical registry Initial treatment in relation to 
clinical stage-at-diagnosis or 
performance status or specific 
prognostic features of the 
cancer
15 (60.0%) 10 (21.3%) 23 48.9%)) 23 (27.7%)) 25 (61.0%) 96 (39.5%)
Participation in clinical trial 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (1.2%) 0 (0.0%) 2 (0.8%)
Assessment by multi-
disciplinary team;
0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (1.2%) 0 (0.0%) 2 (0.8%)
Sub-total 15 (60.0%) 10 (21.2%) 25 (53.2%) 41 (49.4%) 28 (68.3%) 119 (49.0%)
Category 3 Details of surgery; 0 (0.0%) 0 (0.0%) 10 (21.3%) 0 (0.0%) 0 (0.0%) 10 (4.1%)
Extended clinical 
registry medical 
record review,
Treatments for complications 
of cancer treatment
0 (0.0%) 3 (6.4%) 2 (4.3%) 1 (1.2%) 0 (0.0%) 6 (2.5%)
Long-term follow-up; 1 (4.0%) 3 (6.4%) 3 (6.4%) 2 (2.4%) 4 (9.8%) 13 (5.3%)
Management of disease 
progression including pain relief 
and palliation
2 (8.0%) 22 (46.8%) 6 (12.8%) 29 (34.9%) 0 (0.0%) 59 (24.3%)
Sub-total 3 (12.0%) 28 (59.6%) 21 (44.9%) 32 (38.6%) 4 (9.8%) 88 (36.1%)
Category 4 Communication and 
information sharing between 
clinician and patient
7 (28.0%) 9 (19.1%) 1 (2.1%) 5 (6.0%) 6 (14.6%) 28 (11.5%)
Patient interview, 
audio-taping of 
consultation
Grand total 25 (100%) 47 (100%) 47 (100%) 83 (100%) 41 (100%) 243 (100%)Page 4 of 6
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to these factors. The second is the lack of information
about the management of disease progression (24.3%).
Other reasons included the lack of information on initial
diagnostic and staging procedures (7.8%) and long-term
follow-up (5.3%).
There was variation across different cancers (Table 2). For
example, only 9.8% of the melanoma guidelines required
an extended clinical registry or medical record review
(Category 3) because melanoma is less likely to progress
than other cancers and hence there are fewer guidelines
about management of progression. In contrast, 59.6% of
the guidelines for advanced breast cancer were classified
to Category 3, as were 44.9% of the guidelines for colorec-
tal and 38.6% for lung.
Discussion
Population-based registries and administrative inpatient
databases are maintained primarily for other purposes
and can therefore be used to provide feedback measures at
small marginal cost. This is in contrast to clinical regis-
tries, for which feedback and audit are primary functions.
One-off studies based on medical record review (which
we classified to Category 3) are probably less sustainable as
a means of providing regular feedback and the measures
are likely to be less standardised and comparable across
jurisdictions.
The results of this study show that there are two broad
pieces of information that would allow feedback on more
measures using population-based registries and adminis-
trative inpatient data: prognostic factors as measured at
the time of diagnosis (e.g., clinical stage, performance sta-
tus, hormone-receptor status); and information on treat-
ments for disease progression (e.g., recurrences and
metastases), not just initial treatments.
An important prognostic factor is clinical stage and addi-
tion of this data item to population-based registries is
probably an achievable aim, for at least some types of can-
cers [25,26]. For example, a recent Australian report con-
cluded that several types of cancers can be assigned a
clinical TNM stage, based on the data already available to
a population-based registry.[26]
Many clinical registries only collect data on initial treat-
ments, but many guidelines concern the management of
recurrences or metastases. Management decisions about
recurrences or metastases can have an important effect on
the quality-of-life of cancer patients and their carers [27],
so that feedback about disease progression is arguably as
important as feedback about initial treatment.
In recent years, more components of cancer care have
moved from inpatient to ambulatory-care settings, making
it more difficult to obtain complete and accurate data on
cancer care[9]. For the purposes of this study we assumed
that a core clinical registry could collect complete informa-
tion on all initial treatments, even those done in ambula-
tory care settings. In practice, this might not be the case,
with several studies showing that ambulatory care data are
often incomplete, even in those clinical registries that make
special attempts to collect such data [9,10,28,29].
We also assumed that population-based cancer registries
and administrative inpatient data cover the entire popula-
tion, as is the case in Australia. This is not the case in some
countries like the United States where population-based
cancer registries (SEER) are a representative sample and
claims databases for inpatients typically cover only a seg-
ment of the population (e.g., Medicare claims data only
includes patients 65 years or older).
We used clinical practice guidelines to identify processes-
of-care of interest to clinicians. These would need to be
developed into feedback measures, which involves expert
clinical advice and clear exclusion criteria. This current
paper has only assessed the utility of various data sources
for feedback, which is only a small, albeit essential, part of
the process.[30,31]
The starting point for this study was that sometimes there
is a gap between what is currently provided and what
might be provided in ideal circumstances to cancer
patients. If we accept that timely and on-going feedback
can reduce the gap, then we need systems that can rou-
tinely provide data that are of sufficient quality and cover
all patients in a defined population, regardless of whether
they are treated in small hospitals or in large hospitals
with well-developed data systems.[9]
Systematic reviews have shown that for cancer, as for other
conditions, patients tend to have poorer outcomes if they
are treated by a hospital or clinician who treats a relatively
small number of patients with a particular cancer.[32]
Therefore, it is in the smaller hospitals where there are a-
priori concerns about quality of cancer care, but it is usu-
ally only population-based registries or routine-inpatient
databases that cover these hospitals.[11,33] Whether it is
feasible to maintain clinical registries in smaller hospitals
is debatable. This makes providing feedback measures to
smaller hospitals problematic, although these might be
the hospitals where the most gains in quality-of-care can
be made.
Conclusion
The advantages of population-based cancer registries and
administrative inpatient data are wide coverage and low
cost. The disadvantage is that they can currently be used to
report only a few feedback measures. In most jurisdic-
tions, clinical cancer registries, which can be used toPage 5 of 6
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BMC Health Services Research 2009, 9:84 http://www.biomedcentral.com/1472-6963/9/84report many more feedback measures, do not cover
smaller hospitals. If we are to provide feedback about all
patients, not just those in larger academic hospitals with
the most developed data systems, then we need to develop
sustainable population-based data systems that capture
information on prognostic factors at the time of initial
diagnosis and information on management of disease
progression.
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